A Study to Investigate the Safety of DSP-3077 After a Unilateral Eye Injection in Male and Female Participants 18 Years of Age or Older With Retinitis Pigmentosa

Recruiting

Phase 1

Phase 2

DSP-3077A Study to Investigate the Safety of DSP-3077 After a Unilateral Eye Injection in Male and Female Participants 18 Years of Age or Older With Retinitis Pigmentosa

Sponsor:

Sumitomo Pharma America, Inc.

Code:

NCT06891885

Conditions

Retinitis Pigmentosa

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

DSP-3077 Retinal Sheet Cohort 1

DSP-3077 Retinal Sheet Cohort 2

DSP-3077 Retinal Sheet Cohort 3

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2026-02-25. This information was provided to ClinicalTrials.gov by Sumitomo Pharma America, Inc. on 2025-09-23.